Mizuho Securities Reaffirms Their Buy Rating on Corvus Pharmaceuticals (CRVS)

By Ryan Adsit

In a report issued on July 7, Mara Goldstein from Mizuho Securities maintained a Buy rating on Corvus Pharmaceuticals (CRVSResearch Report), with a price target of $7.00. The company’s shares closed last Friday at $4.03.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 12.6% and a 43.2% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Corvus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $9.00, a 130.2% upside from current levels. In a report issued on July 8, H.C. Wainwright also maintained a Buy rating on the stock with a $10.00 price target.

See today’s analyst top recommended stocks >>

Corvus Pharmaceuticals’ market cap is currently $109.4M and has a P/E ratio of -2.60. The company has a Price to Book ratio of 2.58.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer’s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.